BIO Bio-Rad Laboratories, Inc.
Healthcare$296.90+3.18%ClosedMarket Cap: $8.03B
As of 2026-05-26
Valuation
P/E (TTM)
9.92
PEG
0.07
P/B
1.13
P/S
3.00
EV/EBITDA
250.00
DCF Value
$-210.89
FCF Yield
4.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.9%
Operating Margin
9.2%
Net Margin
6.5%
ROE
2.4%
ROA
1.7%
ROIC
2.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $592.1M | 52.3% | $34.1M | $-527.1M | $— | — |
| Q4 null | $693.2M | 49.8% | $61.9M | $720.0M | $— | — |
| FY null | $2.58B | 52.0% | $270.5M | $759.9M | $— | — |
| Q3 null | $653.0M | 52.6% | $66.4M | $-341.9M | $— | — |
| Q2 null | $651.6M | 53.0% | $77.1M | $317.8M | $— | — |
| Q1 null | $585.4M | 52.3% | $23.7M | $64.0M | $— | — |
| Q4 null | $667.5M | 51.2% | $58.3M | $-715.8M | $— | — |
| FY null | $2.57B | 53.7% | $269.0M | $-1.84B | $— | — |
| Q3 null | $649.7M | 54.8% | $64.5M | $653.2M | $— | — |
| Q2 null | $638.5M | 55.6% | $101.5M | $-2.17B | $— | — |
| Q1 null | $610.8M | 53.4% | $52.0M | $383.9M | $— | — |
| Q4 2023 | $681.2M | 53.7% | $97.8M | $349.7M | $12.14 | — |